inPROBE preclinical data
inPROBE as a potential platform for in situ cancer biomarker detection
inPROBE as a potential platform for cancer biomarker detection in liquid samples
inPROBE: antibody specificity and sensitivity for HER2 biomarker detection
Validated ELISA Assay for Precise HER2 Quantification in Cancer Research
A recent peer-reviewed study published in the Journal of Visualized Experiments (JoVE) presents a validated sandwich ELISA assay for the precise detection of Human Epidermal Growth Factor Receptor 2 (HER2). This method enables comprehensive quantification of both membrane-bound and soluble forms of HER2 across various biological matrices, including cell culture media and tissue samples. Developed by the team at SDS Optic, the assay demonstrates high sensitivity and accuracy, offering a useful tool for preclinical research and biomarker monitoring in HER2-expressing cancers.
Advancing HER2 antibody research through in silico docking
This article presents a computational study of how two newly developed monoclonal antibodies interact with the HER2 receptor, a key target in cancer diagnostics and therapy. Using the LightDock docking tool, researchers from SDS Optic S.A. modeled these antibodies against three HER2 protein structures. The analysis identified two recurring binding regions, highlighting potential antigen sites. The results provide important insights into antibody-antigen interactions. The study concludes that while in silico tools like LightDock offer a cost-effective and informative starting point, experimental validation remains crucial to confirm accuracy and guide therapeutic refinement.
HER2 distribution in tumor and blood of mice with xenograft human cancer
The results of our own research indicating the accumulation of the soluble form of the HER2 receptor in the vicinity of the HER2+ tumor were presented at the 34th EORTC NCI AACR Symposium in Barcelona.
We Care About Your Privacy
SDS Optic S.A. uses cookies to improve and customize users experience on our website. By selecting 'Accept', you consent to the use of all cookies that gather and use information about your interactions with our site to provide personalized content and enhance your digital experience. Please read our Privacy Policy for more information.